Evidence map›Paper›PMID 18583934›Full record

ReviewCell cycle (Georgetown, Tex.)2008

New roles for the major human 3'-5' exonuclease TREX1 in human disease.

David Kavanagh, Dirk Spitzer, Parul H Kothari, Aisha Shaikh, M Kathryn Liszewski, Anna Richards, John P Atkinson

2 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Cell cycle (Georgetown, Tex.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02723448 phase1completednot on this mapstarted 2016, after this paper: background citation

A Pilot Study of Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy (RVCL)

TypeinterventionalSponsorWashington University School of MedicineRan2016 to 2020Enrolled4ConditionsVasculopathy, Retinal, With Cerebral Leukodystrophy, Cerebroretinal Vasculopathy, HereditaryArmsaclarubicin
NCT04611880 phase2completednot on this mapstarted 2021, after this paper: background citation

A Trial of Crizanlizumab for the Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)

TypeinterventionalSponsorWashington University School of MedicineRan2021 to 2025Enrolled18ConditionsRVCL - Retinal Vasculopathy Cerebral LeukoencephalopathyArmsCrizanlizumab
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Gigaxonin Potentiates Antiviral Innate Immune Responses by Targeting cGAS and TREX1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Emerging insights from the genetics of cerebral small-vessel disease.Annals of the New York Academy of Sciences · 2020
    Review
  18. Article
  19. TREX1 suppression imparts cancer-stem-cell-like characteristics to CD133International journal of clinical and experimental pathology · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

David KavanaghInstitute of Human Genetics, Newcastle University, Newcastle upon Tyne, United Kingdom.
Dirk Spitzer
Parul H Kothari
Aisha Shaikh
M Kathryn Liszewski
Anna Richards
John P Atkinson
Newcastle University · GB

Funding

TRAINING IN THE IMMUNOLOGY OF RHEUMATIC DISEASEST32AR007279 · NIAMS · WASHINGTON UNIVERSITY · PI Megan Anne Cooper, Deborah J Lenschow · 1986 to 2026
$6.0M
NIAMS NIH HHS T32 AR007279
6 · The paper itself

Abstract

Aicardi-Goutières syndrome (AGS), Systemic Lupus Erythematosus (SLE), Familial Chilblain Lupus (FCL) and Retinal Vasculopathy and Cerebral Leukodystrophy (RVCL) {a new term encompassing three independently described conditions with a common etiology--Cerebroretinal Vasculopathy (CRV), Hereditary Vascular Retinopathy (HVR) and Hereditary Endotheliopathy, Retinopathy and Nephropathy (HERNS)}--have previously been regarded as distinct entities. However, recent genetic analysis has demonstrated that each of these diseases maps to chromosome 3p21 and can be caused by mutations in TREX1, the major human 3'-5' exonuclease. In this review, we discuss the putative functions of TREX1 in relationship to the clinical, genetic and functional characteristics of each of these conditions.

Indexed as

Brain DiseasesExodeoxyribonucleasesGenetic Diseases, InbornHumansLupus Erythematosus, SystemicMutationPhosphoproteinsRetinal DiseasesSjogren's SyndromeExodeoxyribonucleasesPhosphoproteinsthree prime repair exonuclease 1TREX2 protein, human

Identifiers

PMID18583934
PMCPMC2825026
OpenAlexW2150904528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.